| 000 | 00000nam 2200000zi 4500 |
| 001 | 9.907333 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20250107144057 |
|---|
| 006 | m o d f |
|---|
| 007 | cr cn||||||||| |
|---|
| 008 | 220126e202202##oncd obs f000 0 eng d |
|---|
| 020 | |a9780660417950 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH82-29/3-2022E-PDF |
|---|
| 245 | 00|aAlignment among public formularies in Canada, part 3 : |bmedicines assessed by the common drug review. |
|---|
| 264 | 1|aOttawa, ON : |bPatented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, |cFebruary 2022. |
|---|
| 264 | 4|c©2022 |
|---|
| 300 | |a1 online resource (iii, 21 pages) : |bcolour charts |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Concordance des listes de médicaments des régimes publics au Canada, partie 3 : médicaments évalués par le programme commun d'évaluation des médicaments. |
|---|
| 500 | |aIssued also in HTML format. |
|---|
| 504 | |aIncludes bibliographical references. |
|---|
| 520 | |a"This is the last report in a three-part PMPRB series that explores current overlaps and gaps in Canadian public drug plan formularies"--Executive summary, page ii. |
|---|
| 650 | 0|aPharmaceutical services insurance|zCanada|vStatistics. |
|---|
| 650 | 0|aDrugs|zCanada|vStatistics. |
|---|
| 650 | 0|aPharmaceutical policy|zCanada. |
|---|
| 655 | 7|aStatistics|2lcgft |
|---|
| 710 | 1 |aCanada. |bPatented Medicine Prices Review Board, |eissuing body. |
|---|
| 775 | 08|tConcordance des listes de médicaments des régimes publics au Canada, partie 3 : |w(CaOODSP)9.907335 |
|---|
| 856 | 40|qPDF|s2.60 MB|uhttps://publications.gc.ca/collections/collection_2022/cepmb-pmprb/H82-29-3-2022-eng.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/formularies-part3-medicines-assessed.html |
|---|